Payment overview · 2025
General Payments
$363.98
13 reported records · 5 companies
Healthcare provider profile · identity verified
Robert J Hawes, MD
Allopathic & Osteopathic Physicians|Family Medicine · TIFTON, GA · NPI 1518036623
Verified facts
What the public records show
CMS Open Payments records show Robert J Hawes, MD received $363.98 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 41.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.43 | 41.3% | 7 | 2025 |
| Braintree Laboratories, Inc. | Unresolved — no canonical attribution shown | $135.18 | 37.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.70 | 9.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.91 | 7.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.76 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.98 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.43 | 7 | 2025 |
Source payment records
|
|||||
| SUFLAVE Normalized: suflave |
Drug | Braintree Laboratories, Inc. | $135.18 | 1 | 2025 |
Source payment records
|
|||||
| SUTAB Normalized: sutab |
Drug | Braintree Laboratories, Inc. | $135.18 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.29 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 95 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 709 | 206 |
| Atorvastatin Calcium | Atorvastatin Calcium | 581 | 161 |
| Losartan Potassium | Losartan Potassium | 549 | 153 |
| Lisinopril | Lisinopril | 356 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 74 |
| Mounjaro | Tirzepatide | 242 | 36 |
| Omeprazole | Omeprazole | 236 | 71 |
| Jardiance | Empagliflozin | 225 | 51 |
| Gabapentin | Gabapentin | 224 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 40 |
| Metformin Hcl | Metformin Hcl | 183 | 51 |
| Famotidine | Famotidine | 176 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 47 |
| Potassium Chloride | Potassium Chloride | 173 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 50 |
| Ozempic | Semaglutide | 149 | 23 |
| Allopurinol | Allopurinol | 126 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 38 |
| Furosemide | Furosemide | 118 | 35 |
| Sertraline Hcl | Sertraline Hcl | 115 | 33 |
| Glimepiride | Glimepiride | 109 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 29 |
| Eliquis | Apixaban | 95 | 25 |
| Ezetimibe | Ezetimibe | 95 | 27 |
| Carvedilol | Carvedilol | 92 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 24 |
| Montelukast Sodium | Montelukast Sodium | 85 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 23 |
| Pregabalin | Pregabalin | 75 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 16 |
| Metformin Hcl Er | Metformin Hcl | 73 | 24 |
| Buspirone Hcl | Buspirone Hcl | 72 | 23 |
| Trulicity | Dulaglutide | 71 | 19 |
| Bupropion Xl | Bupropion Hcl | 70 | 22 |
| Meloxicam | Meloxicam | 67 | 21 |
| Spironolactone | Spironolactone | 65 | 19 |
| Alendronate Sodium | Alendronate Sodium | 64 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 17 |
| Simvastatin | Simvastatin | 60 | 14 |
| Mirtazapine | Mirtazapine | 58 | 17 |
| Nifedipine Er | Nifedipine | 58 | 16 |
| Donepezil Hcl | Donepezil Hcl | 54 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 16 |
| Clonidine Hcl | Clonidine Hcl | 51 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 20 |
| Terazosin Hcl | Terazosin Hcl | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 16 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Lovastatin | Lovastatin | 43 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 18 |
| Rybelsus | Semaglutide | 40 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 15 |
| Linzess | Linaclotide | 38 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 12 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 13 |
| Valsartan | Valsartan | 27 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Silodosin | Silodosin | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 19 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 13 | suppressed |
| Ulticare Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Finasteride | Finasteride | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.98 · 13 records | Novo Nordisk Inc | ELIQUIS, EVENITY, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SUFLAVE, SUTAB, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error